Dr. Elena Tchetina | Medicine and Dentistry | Excellence in Research Award

Dr. Elena Tchetina | Medicine and Dentistry | Excellence in Research  Award 

Leading Scientist at Nasonova Research Institute of Rheumatology | Russia

Dr. Elena Tchetina is a distinguished researcher in medicine and dentistry, recognized for her impactful contributions to molecular biology and rheumatology. Her academic foundation includes advanced training in microbiology, cell biology, and molecular sciences, supporting a strong interdisciplinary approach to biomedical research. She has extensive experience as a leading scientist and principal investigator, contributing to high-level research in immunology and molecular physiology. Her research interests focus on osteoarthritis, rheumatoid arthritis, and osteoporosis, with emphasis on gene expression, metabolic regulation, and biomarker discovery for disease progression and therapeutic response. Dr. Elena Tchetina has produced 53 documents with an h-index of 18 and has received 8,094 citations across 7,863 documents, reflecting her global research influence. Her work advances translational medicine by connecting molecular insights with clinical applications, strengthening innovative strategies for diagnosis, prognosis, and personalized treatment in rheumatic diseases.

Citation Metrics

8000

7000

6000

5000

4000

Citations
8094

Documents
53

h-index
18

View Scopus ProfileView ORCID Record

Featured Publications

Molecular Mechanisms of Osteoarthritis Progression and Cartilage Degeneration

– International Journal of Molecular Sciences

Gene Expression Signatures in Rheumatoid Arthritis and Therapeutic Targets

– Frontiers in Immunology

Biomarkers for Predicting Disease Progression in Osteoarthritis Patients

– Arthritis Research & Therapy

Metabolic Pathways and Inflammation in Joint Disorders

– Journal of Clinical Medicine

Translational Approaches in Rheumatology: From Molecular Insights to Clinical Practice

– Clinical Rheumatology

Franziska Münz | Medicine and Dentistry | Future Science Leader Award

Dr. Franziska Münz | Medicine and Dentistry | Future Science Leader Award 

Physician at Universität Heidelberg | Germany

Dr. Franziska Münz is a promising researcher in the field of Medicine and Dentistry, demonstrating strong scientific impact through 10 scholarly documents that have collectively received 97 citations across 88 academic works, alongside an h-index of 5. Her research contributions focus on advancing medical knowledge through evidence-based approaches, particularly in clinically relevant and translational domains. Her work reflects a commitment to improving healthcare outcomes by exploring innovative methodologies and interdisciplinary perspectives. With a growing citation record and consistent publication output, Dr. Franziska Münz shows clear potential as an emerging leader in future scientific advancements. Her research trajectory highlights both quality and influence, positioning her as a valuable contributor to the global medical research community and a strong candidate for recognition under the Future Science Leader Award.

Citation Metrics

100

75

50

25

0

Citations
97

Documents
10

h-index
5

View Scopus Profile

Top 5 Publications

Bing Han | Medicine and Dentistry | Outstanding Scientist Award

Dr.Bing Han | Medicine and Dentistry | Outstanding Scientist Award 

Dermatologist at The First Hospital of Jilin University | China

Dr. Bing Han is a medical researcher and clinician specializing in dermatological science with a strong foundation in advanced medical education and academic training. Dr. Bing Han has extensive professional experience integrating clinical practice with translational research, focusing on melanoma, vitiligo, and molecular mechanisms of skin disease progression. The research interests emphasize biomarker discovery, metabolic reprogramming, and therapeutic innovation in dermatology. With 99 scholarly documents, 1,291 citations from 1,231 documents, and an h-index of 22, Dr. Bing Han demonstrates sustained scientific impact and excellence in medical research.

Citation Metrics (Scopus)

1400

1000

600

200

0

Citations
1,291

Documents
99

h-index
22


View Scopus Profile

Featured Publications

Taeyoung Kyong | Medicine and Dentistry | Research Excellence Award

Dr. Taeyoung Kyong | Medicine and Dentistry | Research Excellence Award 

Professor at Yonsei University College of Medicine | South Korea

Dr. Taeyoung Kyong is a medical academic and clinician recognized for expertise in hospital medicine and inpatient care. His education and professional training underpin a strong foundation in internal medicine and clinical research. He has extensive experience integrating patient-centered practice with system-based healthcare improvement. His research interests focus on hospitalist-led care models, diabetes management, quality improvement, and digital health applications. Overall, Dr. Taeyoung Kyong’s work reflects a sustained commitment to advancing evidence-based inpatient medicine and healthcare excellence.

View ORCID

Featured Publications

Sun Jong Kim | In Vitro Diagnostics | Science and Technology Pioneer Award

Dr. Sun Jong Kim | In Vitro Diagnostics | Science and Technology Pioneer Award 

Researcher at BioFront | South Korea

Dr. Sun Jong Kim is a highly accomplished biotechnology and life sciences professional whose career reflects sustained contributions to in vitro diagnostics, stem cell science, biomolecular research, and translational biomedical innovation. Equipped with a strong academic foundation including bachelor’s, master’s, and doctoral studies in life sciences, Dr. Sun Jong Kim has developed deep expertise in cellular biology, developmental biology, and molecular mechanisms of pluripotency. His professional journey includes senior research and leadership roles across multiple biomedical organizations, where he has guided R&D programs involving the establishment and maintenance of pluripotent stem cell lines, large-scale microalgae production systems, medical device development, and regulatory preparation for diagnostic technologies. He has contributed to the development of human embryonic stem cell resources, in vitro differentiation platforms, and advanced diagnostic systems applied to areas such as oncology, COVID-19 rapid testing, and point-of-care technologies. His industrial leadership also includes oversight of product development pipelines, quality assurance systems, and multidisciplinary research operations, demonstrating an ability to translate scientific results into usable biomedical solutions that directly support clinical and research infrastructures. His research outputs include numerous scientific publications, national and international presentations, and patents in areas such as stem cell culturing techniques, photobioreactors, and biomaterial-based innovations. The measurable impact of his scholarly contribution is represented by 24 citations by 24 documents, 2 indexed documents, and an h-index of 2, reflecting ongoing engagement and recognition within the scientific community. Dr. Sun Jong Kim’s research interests encompass stem cell biology, human cell culture systems, the regulation of self-renewal and differentiation pathways, bioprocess design, clinical diagnostics, and biotechnology commercialization. His work has been supported by significant research grants and has contributed to advancements in both academic discovery and applied biomedical engineering. In addition to laboratory research, he has played a crucial role in the development, certification, and evaluation of diagnostic medical devices aligned with international regulatory standards and real-world clinical needs. Through his ongoing work at Biofront and other institutions, Dr. Sun Jong Kim continues to drive innovation in science and technology, contributing to advancements that support more accurate diagnostics, greater understanding of biological systems, and the modernization of biomedical tools used in healthcare and life science research.

Profile: Scopus

Featured Publications:

Kim, S. J.,(1999). Isolation of developmentally regulated novel genes based on sequence identity and gene expression patterns. Molecules and Cells, 9, 207–218.

Kim, S. J.,(2001). Ovarian expression of melatonin Mel(1) receptor mRNA during mouse development. Molecular Reproduction and Development, 59, 126–132.

Kim, S. J.,(2003). Isolation and culture of human embryonic stem-like cells from abnormal blastocysts. Korean Journal of Fertility and Sterility, 30, 293–301.

Kim, S. J.,(2003). Establishment and maintenance of human embryonic stem cells on STO, a permanently growing cell line. Biology of Reproduction, 69, 2007–2014.

Kim, S. J.,(2004). Establishment of embryonic germ cells from cultured human primordial germ cells and their differentiation into neuronal cells. Molecules and Cells, 17, 309–315.

Kim, S. J.,(2004). Recent advances in human embryonic stem cell research. Journal of the Korean Medical Association, 918–925.

Kim, S. J.,(2004). Effects of type IV collagen and laminin on the cryopreservation of human embryonic stem cells. Stem Cells, 22, 950–961.

Kim, S. J.,(2004). Available human feeder cells for the maintenance of human embryonic stem cells. Reproduction, 128, 727–735.

Javier Baena Espinar | Medicine and Dentistry | Best Research Article Award

Dr. Javier Baena Espinar | Medicine and Dentistry | Best Research Article Award 

Medical Oncologist at Hospital 12 de Octubre | Spain

Dr. Javier Baena Espinar is a prominent medical oncology researcher whose work has significantly shaped contemporary understanding of thoracic malignancies, precision oncology, and real-world clinical outcomes. His academic background is grounded in advanced training in health sciences, biomedicine, molecular oncology, immuno-oncology, and cancer biology, supported by multiple postgraduate degrees and specialized certifications that have strengthened his expertise in lung cancer research and evidence-based clinical practice. His professional experience spans leading Spanish healthcare and research institutions, where he has contributed to multidisciplinary oncology teams, national research initiatives, and international collaborative networks focused on improving diagnostic accuracy, treatment personalization, and therapeutic decision-making. His research interests center on non-small cell lung cancer, small cell lung cancer, immune checkpoint inhibitors, next-generation sequencing, biomarker discovery, outcomes research, and the intersection between cancer care and infectious disease vulnerabilities. He has been instrumental in studies evaluating immunotherapy effectiveness, prognostic determinants, molecular profiling, and global registry data, producing findings that support the optimization of treatment strategies and guide clinical standards. With 27 published documents, 884 citations from 800 referencing articles, and an h-index of 11, his scholarly contributions reflect sustained impact and influence across oncology and translational research communities. His work appears in high-impact journals and encompasses both clinical and translational dimensions, bridging innovative scientific methodologies with real-world applicability. Through continuous involvement in international collaborations, multicenter studies, and academic dissemination, he has advanced the understanding of patient outcomes, therapeutic safety, and emerging frontiers in cancer treatment. His research trajectory demonstrates a strong commitment to expanding precision medicine, fostering collaborative research excellence, and improving the clinical management of thoracic cancers. Dr. Javier Baena Espinar’s ongoing contributions highlight his dedication to advancing scientific knowledge, strengthening global oncology evidence, and supporting the evolution of patient-centered cancer care.

Profile: Scopus | Orcid

Featured Publications:

  • Baena Espinar, J. (2025). Determinants of 5-year survival in patients with advanced NSCLC with PD-L1 ≥50% treated with first-line pembrolizumab outside clinical trials: Pembro-real 5Y registry results. Journal for Immunotherapy of Cancer.

  • Baena Espinar, J., et al. (2025). Clinical utility of combined tissue and plasma next-generation sequencing in treatment-naïve advanced NSCLC. JTO Clinical and Research Reports.

  • Baena Espinar, J., et al. (2025). Efficacy and safety of lorlatinib in ALK- and ROS1-rearranged metastatic NSCLC within the compassionate use program in Spain.

  • Baena Espinar, J., et al. (2025). Observational study on the safety and effectiveness of SARS-CoV-2 vaccination in lung cancer patients.

  • Baena Espinar, J., et al. (2025). Safety and efficacy of immune checkpoint therapy in patients with cardiac metastasis: A multicenter international retrospective analysis.

  • Baena Espinar, J., et al. (2025). Unmet needs in maintenance therapy for extensive-stage small cell lung cancer.

  • Baena Espinar, J. (2024). Consolidation osimertinib vs durvalumab vs observation after chemoradiation in unresectable EGFR-mutant NSCLC. Journal of Thoracic Oncology.

  • Baena Espinar, J.(2024). Facts and hopes on cancer immunotherapy for small cell lung cancer. Clinical Cancer Research.

  • Baena Espinar, J.(2024). Real-world data of first-line cemiplimab monotherapy for PD-L1 high NSCLC. Journal of Thoracic Oncology.

  • Baena Espinar, J.(2024). Multi-region transcriptomic subtyping and biomarkers of chemoimmunotherapy outcome in extensive-stage SCLC. Clinical Cancer Research.

  • Baena Espinar, J.(2024). Targeting KRAS G12C in NSCLC: Current standards and developments. Drugs.

  • Baena Espinar, J.(2023). Future perspectives in second-line therapy for non-oncogene–addicted NSCLC. Cancers.

  • Baena Espinar, J. (2023). Safety and activity of immune checkpoint inhibitors in people living with HIV and cancer. Journal of Clinical Oncology.

  • Baena Espinar, J.(2022). Updated prognostication system for thoracic malignancies with COVID-19: TERAVOLT registry. Journal of Thoracic Oncology.

  • Baena Espinar, J. (2022). COVID-19 outcomes, vaccination status, and cancer-related delays during the Omicron wave: TERAVOLT analysis. JTO Clinical and Research Reports.

Tom Schimanski | Medicine and Dentistry | Best Researcher Award

Mr. Tom Schimanski | Medicine and Dentistry | Best Researcher Award  

Student at Universität Regensburg | Germany

Mr. Tom Schimanski is an emerging researcher at Universität Regensburg whose work bridges the intersection of medicine, surgery and biomedical innovation. His academic background reflects an early commitment to scientific rigor and medical advancement, culminating in advanced studies and a doctoral research focus within the Department of Plastic, Hand, and Reconstructive Surgery. Building upon a foundation of clinical training, he has developed extensive expertise in translational medicine, integrating laboratory research with real-world surgical applications. His scholarly engagement is marked by active participation in experimental studies addressing tissue regeneration, cellular responses, and cryopreservation methodologies for adipose and connective tissues. Mr. Tom Schimanski’s contributions to the scientific community are evident through his publications in internationally indexed journals such as Cells, where his research explores mechanisms of ferroptosis, biocompatibility of anesthetics, exosome mediated cellular communication, and innovative imaging approaches like multispectral optoacoustic tomography. With 3 published documents, 1 citation, and an h-index of 1, he exemplifies the diligence and precision of a young scientist dedicated to building a lasting impact in medical science. His ongoing collaborations with institutions such as Helmholtz Zentrum München further strengthen his multidisciplinary approach, combining cellular biology, materials science, and reconstructive medicine. Mr. Tom Schimanski’s research interests encompass tissue engineering, regenerative medicine, biomaterials development, and translational surgery, focusing on developing clinically viable strategies to enhance wound healing and graft preservation. His work also reflects a broader vision for integrating biotechnological innovations into surgical practice, fostering advancements that align patient safety with scientific discovery. Through his deep engagement in both experimental and clinical contexts, he continues to advance methodologies that could redefine regenerative outcomes and improve the sustainability of reconstructive procedures. With a growing research record and a strong foundation in evidence-based medicine, Mr. Tom Schimanski represents a new generation of clinician-scientists whose contributions are shaping the evolving landscape of biomedical research and surgical innovation. His pursuit of excellence underscores a commitment to translating science into tangible medical progress, marking him as a promising and impactful figure in contemporary medical research.

Profile: Scopus | Orcid

Featured Publications:

Schimanski, T., Loucas, R., Loucas, M., Brébant, V., Anker, A., Klein, S., Diesch, S. T., Pagani, A., & Prantl, L. (2025). Histological and immunohistochemical characteristics of mechanically processed adipose tissue A systematic review and meta-analysis. Cells, 14(21), 1664.

Schimanski, T., Prantl, L., Eigenberger, A., Felthaus, O., Loucas, R., Utpatel, K., & Steer, K. (2025). CELTPLUS fat increases the metabolic activity as well as the SVF-yield significantly when compared to CELT fat, even after cryopreservation with DMSO. Cells, 14(16), 1270.

Schimanski, T., Loucas, R., Loucas, M., Felthaus, O., Brébant, V., Klein, S., Anker, A., Frank, K., Siegmund, A., Pagani, A., & Prantl, L. (2025). Histology and immunohistochemistry of adipose tissue: A scoping review on staining methods and their informative value. Cells, 14(12), 898.

Eigenberger, A., Felthaus, O., Bartsch, A., Schimanski, T., Utpatel, K., & Prantl, L. (2025). The influence of sedimentation on the composition of the lipoaspirate and the effects on further mechanical processing. Cells, 14(8), 601.

Iker Alonso González | Medicine and Dentistry | Best Researcher Award

Mr. Iker Alonso González | Medicine and Dentistry | Best Researcher Award 

FACULTATIVO ESPECIALISTA MEDICO-TECNICO EN MICROBIOLOGÍA Y PARASITOLOGÍA at Cruces University Hospital | Spain

Mr. Iker Alonso González is a dedicated researcher and professional in the field of microbiology and clinical parasitology, recognized for his growing contributions to medical and pharmaceutical sciences. He holds a degree in Pharmacy from the University of the Basque Country (UPV/EHU) and has further specialized in Microbiology and Clinical Parasitology at Cruces University Hospital, where he continues to advance his expertise in infectious disease research and diagnostics. His professional experience at Osakidetza the Basque Health Service combines clinical practice with applied research, focusing on microbial resistance, infectious disease control, and antibiotic stewardship. He has presented numerous research communications, including fourteen posters and two oral presentations at the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), addressing critical topics such as antimicrobial resistance patterns in Shigella spp. and the clinical impact of post-treatment uroculture interventions. His scientific publication, “Multiresistant Aeromonas hydrophila bacteremia,” published in Enferm Infecc Microbiol Clin (Engl Ed), reflects his analytical approach and contribution to understanding emerging multidrug-resistant pathogens. His current research interests center around the development of evidence-based antimicrobial protocols, optimization of laboratory diagnostics, and epidemiological monitoring of infectious diseases in clinical settings. Mr. Iker Alonso González’s participation in national research forums and professional societies highlights his commitment to academic collaboration and scientific advancement. His early scholarly impact is reflected in his record of 2 citations by 2 documents, 3 published works, and an h-index of 1, indicating a promising trajectory in medical research. He is also engaged in continuous professional development, ensuring alignment with global standards in clinical microbiology and pharmaceutical practice. Through his rigorous research, clinical application, and scholarly engagement, Mr. Iker Alonso González exemplifies the integration of scientific inquiry and healthcare innovation, contributing to the ongoing efforts to enhance antimicrobial stewardship and patient outcomes in contemporary medicine.

Profile: Scopus

Featured Publications:

  • Alonso-González, I. (2025). Upper limb abscess due to an unusual Clostridium species in an immunocompetent child. Enfermedades Infecciosas y Microbiología Clínica.

  • Alonso-González, I. (2023). Sensitivity profile of Shigella spp. isolates in patients with travelers’ diarrhea in a tertiary hospital in the period 2017–2022. Presented at the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC).

  • Alonso-González, I. (2023). Impact of a PROA intervention on the request of non-proven post-treatment control urocultures. Presented at the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC).

  • Alonso-González, I. (2022). Multiresistant Aeromonas hydrophila bacteremia. Enfermedades Infecciosas y Microbiología Clínica

 

Barbara Ariue | Medicine and Dentistry | Best Researcher Award

Dr. Barbara Ariue | Medicine and Dentistry | Best Researcher Award 

Dr. Barbara Ariue is a distinguished medical professional and academic leader specializing in pediatric allergy and immunology, recognized for her outstanding contributions to research, education, and clinical innovation. As an Associate Professor of Pediatrics at a leading medical institution, she has dedicated her career to advancing the understanding and management of pediatric asthma, allergic conditions, stinging insect allergies, and immunodeficiency disorders. Her academic journey reflects a deep commitment to excellence in both teaching and scientific inquiry, inspiring medical students and resident physicians to pursue evidence-based and compassionate patient care. Dr. Barbara Ariue’s research has significantly impacted the field, particularly through her pioneering project, “Addressing Knowledge Gaps in Diagnosing and Managing Inborn Errors of Immunity,” which received a planning grant from the Allergists’ Foundation Community Grant Program under the American College of Allergy, Asthma, and Immunology. The project evaluates diagnostic practices, interdisciplinary collaboration, and educational needs in managing immunodeficiencies, leading to her recent publication, “Lessons from the ACAAI Survey: Advancing the Diagnostic and Therapeutic Strategies for the Practicing Allergist-Immunologist,” in the Annals of Allergy, Asthma, and Immunology. Her scholarly output includes publications in prestigious journals such as Journal of Clinical Immunology, Pediatrics, and Biochemical and Biophysical Research Communications. In addition to her research, she serves as a consultant and advisory board member for various pharmaceutical organizations, contributing her expertise to clinical trials and therapeutic advancements in immunology. Professionally, she holds fellowships and leadership positions in numerous medical societies, including the American College of Allergy, Asthma, and Immunology, and the American Academy of Pediatrics, reflecting her influence in shaping professional standards in allergy and immunology. Her citation index demonstrates 168 citations by 168 documents, with 11 publications and an h-index of 6, underscoring the impact and reach of her scientific work. Dr. Barbara Ariue’s career embodies a balance of clinical dedication, academic leadership, and research excellence, with her contributions continually shaping the future of pediatric immunology and fostering global advancements in medical science and patient care.

Profile: Scopus | Orcid  

Featured Publications:

  • Oh, C. K., Ariue, B., Alban, R. F., Shaw, B., & Cho, S. H. (2002). PAI-1 promotes extracellular matrix deposition in the airways of a murine asthma model. Biochemical and Biophysical Research Communications, 294(5), 1155–1160.

  • Heimall, J., Keller, M., Saltzman, R., Bunin, N., McDonald-McGinn, D., Ariue, B., … Markert, M. L. (2012). Diagnosis of 22q11.2 deletion syndrome and Artemis deficiency in two children with T-B-NK+ immunodeficiency. Journal of Clinical Immunology, 32(5), 1141–1144.

  • Cho, S. H., Hall, I. P., Wheatley, A., Ariue, B. K., Abraha, D., Delmundo, J., & Oh, C. K. (2001). The possible role of plasminogen activator inhibitor-1 gene in the development of asthma. Journal of Allergy and Clinical Immunology, 107.

  • Ariue, B. K., Cho, S. H., Tam, S. W., & Oh, C. K. (2001). 142 Analysis of airway remodeling genes in human mast cells by cDNA microarrays. Journal of Allergy and Clinical Immunology, 107.

  • Ariue, B. K. & Oh, C. K. (2005). Chapter 43 – Anaphylaxis (in book chapter). In Pediatrics. Mosby Inc.

  • Ariue, B. K. & Oh, C. K. (2005). Chapter 48 – Insect allergies (in book chapter). In Pediatrics. Mosby Inc.

  • McDonnell, J., Angarola, B., Ariue, B., Arnold, D. E., Assa’ad, A. H., Aytekin, C., … Bleesing, J. (2024). COVID-19 vaccination in patients with inborn errors of immunity reduces hospitalization and critical care needs: a USIDNET report. Journal of Clinical Immunology.

Ivan Hancco Zirena | Medicine and Dentistry | Lifetime achievement Award

Prof.Dr.Ivan Hancco Zirena | Medicine and Dentistry | Lifetime achievement Award

post doc at Harvard Medical School, Peru.

Dr. Ivan Hancco Zirena is a distinguished Peruvian physician and researcher specializing in clinical hematology, physiology, and high-altitude medicine. With a rich academic and clinical background spanning multiple continents, Dr. Hancco has carved a niche in understanding human adaptation to hypoxia and extreme environments. Currently serving as a postdoctoral researcher at the Thrombosis and Hemostasis Unit at Harvard Medical School’s Beth Israel Deaconess Medical Center, he contributes to groundbreaking studies on coagulation, red cell physiology, and novel antithrombotic agents.

Profile:

🎓 Educational Background:

Dr. Hancco earned his M.D. from the Universidad Nacional del Altiplano in Puno, Peru (2003), and later specialized in Hematology at Universidad Ricardo Palma, Lima. He pursued advanced studies in France, completing a Master’s in Integrated Biology and Physiology at Université Claude Bernard Lyon 1, followed by a Ph.D. in Physiology at Université Grenoble Alpes. His doctoral thesis investigated hematological responses in high-altitude populations living above 5,000 meters, under the supervision of Dr. Samuel Verges. He is currently completing a postdoctoral fellowship at Harvard Medical School (2023–2025).

💼 Professional Experience:

Dr. Hancco brings extensive experience in both clinical and academic medicine. He has worked in emergency care, hematology units, and cardiovascular rehabilitation in Peru, France, and Spain. His research roles at Laboratoire HP2 (France) and currently at Harvard Medical School (USA) have sharpened his focus on high-impact clinical studies. Additionally, he has provided care to patients with benign and malignant hematologic diseases in military and public hospitals.

Research Interests:

Dr. Hancco’s primary research explores the physiological and hematological adaptations to hypoxia, chronic mountain sickness, erythrocytosis, and cardiovascular and thrombotic responses at high altitudes. His recent work delves into the role of thiol isomerases in hemostasis and thrombosis, with applications in vascular medicine and novel antithrombotic therapies. His interdisciplinary approach bridges physiology, hematology, environmental medicine, and cellular biology.

Teaching Experience:

A passionate educator, Dr. Hancco has taught hematology, physiology, and molecular biology at top Peruvian universities including Universidad de San Martín de Porres, Universidad Científica del Sur, and Universidad Nacional del Altiplano. He has led student research groups, facilitated international exchange programs, and integrated research into medical training. His teaching style fosters critical thinking, debate, and hands-on learning in laboratory and clinical environments.

Skills:

Dr. Hancco is skilled in a wide array of biomedical techniques including flow cytometry, cell culture, platelet aggregation, protein purification, magnetic cell levitation, cytokinesis analysis, microscopy, and complete blood count analysis. These tools have supported his innovative research in hypoxia and hemostasis.

🏅 Recognition and Impact:

Dr. Hancco’s research on chronic mountain sickness and thrombosis has global relevance, particularly for populations living in extreme altitudes. His findings contribute to improved diagnostic and therapeutic strategies for hematological disorders in both high- and low-altitude settings. His work has earned him collaboration with world-renowned institutions and recognition as a rising figure in global hematology and physiology.

Publications:

  • Galloylated polyphenols represent a new class of antithrombotic agents with broad activity against thiol isomerases.
    Journal of Thrombosis and Haemostasis, 2025.

  • Cerebral blood flow in Andean children and adolescents living above 5,000 m.
    Journal of Neurophysiology, 2025.

  • Neurological manifestations associated with exercise at altitude.
    Current Neurology and Neuroscience Reports, 2025.

  • Pain perception threshold in young high-altitude natives after acute exposure to severe hypoxic conditions.
    Oxygen (Basel), 2025.

  • Micro- and macrovascular function in the highest city in the world: A cross-sectional study.
    Lancet Regional Health – Americas, 2024.

  • Performance in the six-minute walking test does not discriminate excessive erythrocytosis patients in a severe hypoxic environment.
    International Journal of Environmental Research and Public Health, 2024.

  • Expedition 5300: Limits of human adaptations in the highest city in the world.
    Journal of Physiology, 2024.

  • Cerebral homeostasis and orthostatic responses in residents of the highest city in the world.
    Scientific Reports, 2024.

  • Lower glycemia levels in subjects with excessive erythrocytosis during the oral glucose tolerance test living in conditions of severe hypoxia.
    Frontiers in Physiology, 2024.

  • Are coagulation profiles in Andean highlanders with excessive erythrocytosis favouring hypercoagulability?
    Experimental Physiology, 2024.